<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03021928</url>
  </required_header>
  <id_info>
    <org_study_id>CR-16-191</org_study_id>
    <nct_id>NCT03021928</nct_id>
  </id_info>
  <brief_title>Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation</brief_title>
  <acronym>START</acronym>
  <official_title>Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas at Austin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lone Star Stroke Research Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas Department of State Health Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas at Austin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Title:

      Optimal Delay Time to Initiate Anticoagulation after Ischemic Stroke in Atrial Fibrillation
      (START): a pragmatic, adaptive randomized clinical trial.

      Primary Objective:

      â€¢ To determine the optimal time to initiate anticoagulation with a Non-Vitamin K Oral
      Anticoagulant (NOAC) after ischemic stroke in patients with non-valvular atrial fibrillation.

      Secondary Objectives:

        -  To compare the rates of primary adverse outcomes in a per protocol analysis

        -  To compare 30 day clinical outcomes by the modified Rankin scale among the
           time-to-treatment groups

        -  To compare 90 day clinical outcomes by the modified Rankin scale among the
           time-to-treatment groups

        -  To explore the optimal timing in subgroups of age, sex, outcome category, and NOAC
           choice
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Long-term oral anticoagulation is standard for secondary stroke prevention in patients with
      atrial fibrillation (AFib). However, there is limited data and no consensus on the timing of
      when to initiate anticoagulation therapy, and concern that starting too soon risks
      symptomatic hemorrhagic transformation. These data are derived almost exclusively from
      heparins and Vitamin K antagonists (e.g.,warfarin). Now that NOACs have become the mainstay
      of stroke prophylaxis in AFib and have more rapid and consistent anticoagulation and fewer
      strokes (hemorrhagic especially), the question of optimal timing of NOAC initiation is of
      increasing importance.

      The primary aim is to determine the time-to-treatment interval with the lowest associated
      risk for adverse events in the context of anticoagulation therapy with NOACs for acute stroke
      patients with non-valvular AFib. The question will be investigated with a prospective,
      adaptive, randomized, controlled &quot;dose-exploration&quot; trial with the time to treatment with
      NOAC therapy treated as the incremental &quot;dose&quot;.

      An adaptive, pragmatic trial will be performed that will not deviate from the treating
      physicians' usual practice except for randomizing the time to start the NOAC. Data collection
      will be limited to those fields necessary for the planned primary and secondary analyses.

      The composite primary outcome event will be any of the following within 30 days of the index
      stroke: Ischemic Events (symptomatic ischemic stroke or systemic embolism), Hemorrhagic
      Events (symptomatic hemorrhagic transformation of index ischemic stroke, other symptomatic
      intracranial hemorrhage, or major extracranial hemorrhage), or all-cause mortality.

      Four time-to-treatment intervals, i.e. study arms, between 2 and 14 days will be
      investigated: 60 hours, 132 hours, 228 hours, and 324 hours. An innovative adaptive design
      will be used which includes response adaptive randomization and modeling of ischemic and
      hemorrhagic outcome events. The ischemic and hemorrhagic events within the composite primary
      endpoint are modeled separately using their known monotonic property that the risk of an
      event increases (ischemic) or decreases (hemorrhage) as the time-to-treatment interval
      lengthens. Interim analyses will occur after every 50 subjects are randomized, where the
      primary outcome will be analyzed and new randomization probabilities will be calculated to
      favor the arms that have a better risk-profile.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2017</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent IschemicEvent</measure>
    <time_frame>30 days</time_frame>
    <description>Any symptomatic ischemic stroke or systemic embolism as evidenced by either CT or MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemorrhagic Event</measure>
    <time_frame>30 days</time_frame>
    <description>Any symptomatic hemorrhagic transformation of index ischemic stroke, other symptomatic intracranial hemorrhage, or major extracranial hemorrhage as evidenced by CT or MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-Cause Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Any</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale</measure>
    <time_frame>30 days</time_frame>
    <description>A modified Rankin scale (mRS) assessment will be performed by a qualified staff member.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale</measure>
    <time_frame>90 days</time_frame>
    <description>A modified Rankin scale (mRS) assessment will be performed by a qualified staff member.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>60 hours</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 60 hours correlates to starting treatment on Day 3, 132 hours starts on Day 5, 228 hours starts on Day 9, and 324 hours starts Day 13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>132 hours</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 60 hours correlates to starting treatment on Day 3, 132 hours starts on Day 5, 228 hours starts on Day 9, and 324 hours starts Day 13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>228 hours</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 60 hours correlates to starting treatment on Day 3, 132 hours starts on Day 5, 228 hours starts on Day 9, and 324 hours starts Day 13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>324 hours</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 60 hours correlates to starting treatment on Day 3, 132 hours starts on Day 5, 228 hours starts on Day 9, and 324 hours starts Day 13.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Time-To-Treatment Randomization</intervention_name>
    <description>The time after symptom onset to initiate treatment will be randomized to one of four possible treatment arms: 60 hours, 132 hours, 228 hours, or 324 hours (+/- 12 hours each).</description>
    <arm_group_label>60 hours</arm_group_label>
    <arm_group_label>132 hours</arm_group_label>
    <arm_group_label>228 hours</arm_group_label>
    <arm_group_label>324 hours</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. New ischemic stroke with disabling neurological deficit or lesion diameter on brain
             imaging &gt; 1.5 cm.

          2. Non-valvular atrial fibrillation (paroxysmal, persistent, or permanent).

          3. Not currently anticoagulated (except for DVT prophylaxis).

          4. Treating physician plans to anticoagulate with a novel oral anticoagulant (NOAC):
             apixaban, dabigatran, edoxaban, or rivaroxaban, or other NOAC.

          5. Qualifying brain CT or MRI scan &lt; 48hr from stroke onset (time last known well). If
             patient has been treated with thrombolytic or endovascular therapy for this stroke,
             then the qualifying scan is performed 18-36 hours after therapy to rule out clinically
             significant hemorrhagic transformation. This group of patients must have their
             qualifying NIHSS assessment performed at the time of this scan.

          6. Ability to randomize within 60 hours of symptom onset.

        Exclusion Criteria:

          1. Primary intracerebral hemorrhage on qualifying neuroimaging. Note: Hemorrhagic
             transformation of a primarily ischemic stroke may be included as per Investigator`s
             judgment. Sporadic microbleeds may be included as per Investigator`s judgment. As a
             general recommendation, a cerebral microbleed is considered to be â‰¤ 5mm, but sometimes
             up to 10mm, in greatest diameter on gradient recalled echo (GRE), or T2*, MRI
             sequences. Any blood visualized on a CT will be classified as a macrobleed

          2. Infarct volume (estimated) is greater than 50% of middle cerebral artery territory on
             qualifying scan.

          3. NIHSS &lt; 4 or &gt; 23 prior to enrollment. Note: For patients that had thrombolytic or
             endovascular therapy, the qualifying NIHSS assessment is that which is obtained
             concurrently with their qualifying scan 18 -36 hours following therapy.

          4. Anticipated need for major surgery over the next 30 days that would require delay,
             discontinuation, or extended suspension of anticoagulant.

          5. Symptomatic edema expected from size and location of ischemic stroke.

          6. Decreased level of consciousness present or expected.

          7. Any intracranial hemorrhage within the previous 6 months.

          8. Life expectancy less than 90 days.

          9. Follow-up in person or by telephone for 90 days is not feasible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Warach, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dell Medical School at The University of Texas at Austin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Truman J Milling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dell Medical School at The University of Texas at Austin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Lawrence, BS</last_name>
    <role>Study Chair</role>
    <affiliation>Dell Medical School at The University of Texas at Austin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Lawrence, BS</last_name>
    <phone>512-324-7000</phone>
    <phone_ext>77396</phone_ext>
    <email>plawrence@seton.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Betsy Sansom, BSN, RN</last_name>
    <phone>512-324-7000</phone>
    <phone_ext>83145</phone_ext>
    <email>BMSansom@seton.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dell Seton Medical Center at The University of Texas</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Lawrence, BS</last_name>
      <phone>512-324-7000</phone>
      <phone_ext>77396</phone_ext>
      <email>plawrence@seton.org</email>
    </contact>
    <investigator>
      <last_name>Steven Warach, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Truman J Milling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ming Ding, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jefferson Miley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seton Medical Center Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Lawrence, BS</last_name>
      <phone>512-324-7000</phone>
      <phone_ext>77396</phone_ext>
      <email>plawrence@seton.org</email>
    </contact>
    <investigator>
      <last_name>Steven Warach, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Truman J Milling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ming Ding, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jefferson Miley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seton Medical Center Hays</name>
      <address>
        <city>Kyle</city>
        <state>Texas</state>
        <zip>78640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Lawrence, BS</last_name>
      <phone>512-324-7000</phone>
      <phone_ext>77396</phone_ext>
      <email>plawrence@seton.org</email>
    </contact>
    <investigator>
      <last_name>Steven Warach, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Truman J Milling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ming Ding, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jefferson Miley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seton Medical Center Williamson</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78665</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Lawrence, BS</last_name>
      <phone>512-324-7000</phone>
      <phone_ext>77396</phone_ext>
      <email>plawrence@seton.org</email>
    </contact>
    <investigator>
      <last_name>Steven Warach, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Truman J Milling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ming Ding, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jefferson Miley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://lonestarstroke.com/</url>
    <description>Website for the Lone Star Stroke Consortium</description>
  </link>
  <reference>
    <citation>JÃ¸rgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke. 1996 Oct;27(10):1765-9.</citation>
    <PMID>8841326</PMID>
  </reference>
  <reference>
    <citation>Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner SJ, Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 Jul;45(7):2160-236. doi: 10.1161/STR.0000000000000024. Epub 2014 May 1. Erratum in: Stroke. 2015 Feb;46(2):e54.</citation>
    <PMID>24788967</PMID>
  </reference>
  <reference>
    <citation>The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet. 1997 May 31;349(9065):1569-81.</citation>
    <PMID>9174558</PMID>
  </reference>
  <reference>
    <citation>Lee JH, Park KY, Shin JH, Cha JK, Kim HY, Kwon JH, Oh HG, Lee KB, Kim DE, Ha SW, Cho KH, Sohn SI, Oh MS, Yu KH, Lee BC, Kwon SU. Symptomatic hemorrhagic transformation and its predictors in acute ischemic stroke with atrial fibrillation. Eur Neurol. 2010;64(4):193-200. doi: 10.1159/000319048. Epub 2010 Aug 12.</citation>
    <PMID>20714158</PMID>
  </reference>
  <reference>
    <citation>January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014 Dec 2;130(23):2071-104. doi: 10.1161/CIR.0000000000000040. Epub 2014 Mar 28. Erratum in: Circulation. 2014 Dec 2;130(23):e270-1.</citation>
    <PMID>24682348</PMID>
  </reference>
  <reference>
    <citation>Sandercock PA, Counsell C, Kane EJ. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev. 2015 Mar 12;(3):CD000024. doi: 10.1002/14651858.CD000024.pub4. Review.</citation>
    <PMID>25764172</PMID>
  </reference>
  <reference>
    <citation>Kim TH, Kim JY, Mun HS, Lee HY, Roh YH, Uhm JS, Pak HN, Lee MH, Joung B. Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in non-valvular atrial fibrillation patients: a multicenter propensity-matched analysis. J Thromb Haemost. 2015 Feb;13(2):182-90. doi: 10.1111/jth.12810. Epub 2015 Jan 7.</citation>
    <PMID>25472735</PMID>
  </reference>
  <reference>
    <citation>Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di Pasquale G, Yusuf S; RE-LY study group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010 Dec;9(12):1157-1163. doi: 10.1016/S1474-4422(10)70274-X. Epub 2010 Nov 6. Erratum in: Lancet Neurol. 2011 Jan;10(1):27.</citation>
    <PMID>21059484</PMID>
  </reference>
  <reference>
    <citation>You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GYH. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e531S-e575S. doi: 10.1378/chest.11-2304.</citation>
    <PMID>22315271</PMID>
  </reference>
  <reference>
    <citation>Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M; ANNEXA-4 Investigators. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2016 Sep 22;375(12):1131-41. doi: 10.1056/NEJMoa1607887. Epub 2016 Aug 30.</citation>
    <PMID>27573206</PMID>
  </reference>
  <reference>
    <citation>Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014 Mar 15;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.</citation>
    <PMID>24315724</PMID>
  </reference>
  <reference>
    <citation>Paciaroni M, Agnelli G, Falocci N, Caso V, Becattini C, Marcheselli S, Rueckert C, Pezzini A, Poli L, Padovani A, Csiba L, SzabÃ³ L, Sohn SI, Tassinari T, Abdul-Rahim AH, Michel P, Cordier M, Vanacker P, Remillard S, Alberti A, Venti M, Scoditti U, Denti L, Orlandi G, Chiti A, Gialdini G, Bovi P, Carletti M, Rigatelli A, Putaala J, Tatlisumak T, Masotti L, Lorenzini G, Tassi R, Guideri F, Martini G, Tsivgoulis G, Vadikolias K, Liantinioti C, Corea F, Del Sette M, Ageno W, De Lodovici ML, Bono G, Baldi A, D'Anna S, Sacco S, Carolei A, Tiseo C, Acciarresi M, D'Amore C, Imberti D, Zabzuni D, Doronin B, Volodina V, Consoli D, Galati F, Pieroni A, Toni D, Monaco S, Baronello MM, Barlinn K, Pallesen LP, Kepplinger J, Bodechtel U, Gerber J, Deleu D, Melikyan G, Ibrahim F, Akhtar N, Mosconi MG, Bubba V, Silvestri I, Lees KR. Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing: The RAF Study. Stroke. 2015 Aug;46(8):2175-82. doi: 10.1161/STROKEAHA.115.008891. Epub 2015 Jun 30.</citation>
    <PMID>26130094</PMID>
  </reference>
  <reference>
    <citation>Abdul-Rahim AH, Fulton RL, Frank B, Tatlisumak T, Paciaroni M, Caso V, Diener HC, Lees KR; VISTA collaborators. Association of improved outcome in acute ischaemic stroke patients with atrial fibrillation who receive early antithrombotic therapy: analysis from VISTA. Eur J Neurol. 2015 Jul;22(7):1048-55. doi: 10.1111/ene.12577. Epub 2014 Oct 16.</citation>
    <PMID>25319957</PMID>
  </reference>
  <reference>
    <citation>Shibazaki K, Kimura K, Aoki J, Saji N, Sakai K. Early initiation of new oral anticoagulants in acute stroke and TIA patients with nonvalvular atrial fibrillation. J Neurol Sci. 2013 Aug 15;331(1-2):90-3. doi: 10.1016/j.jns.2013.05.016. Epub 2013 Jun 3.</citation>
    <PMID>23743245</PMID>
  </reference>
  <reference>
    <citation>Bohmann F, Mirceska A, Pfeilschifter J, Lindhoff-Last E, Steinmetz H, Foerch C, Pfeilschifter W. No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke. PLoS One. 2012;7(7):e40804. doi: 10.1371/journal.pone.0040804. Epub 2012 Jul 24.</citation>
    <PMID>22911709</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2017</study_first_submitted>
  <study_first_submitted_qc>January 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2017</study_first_posted>
  <last_update_submitted>June 20, 2017</last_update_submitted>
  <last_update_submitted_qc>June 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas at Austin</investigator_affiliation>
    <investigator_full_name>Steven Warach</investigator_full_name>
    <investigator_title>Director; Professor</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>NOAC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

